Evidence map›Paper›PMID 40266329›Full record

ArticleHuman genetics2025

Harnessing genotype and phenotype data for population-scale variant classification using large language models and bayesian inference.

Toby R Manders, Christopher A Tan, Yuya Kobayashi, Alexander Wahl, Carlos Araya, Alexandre Colavin, Flavia M Facio, Hillery Metz, Jason Reuter, Laure Frésard and 4 more

Abstract read
In one paragraph

Article in Human genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Toby R MandersLabcorp Genetics Inc, 1400 16th Street, San Francisco, CA, 94103, USA. toby.manders@labcorp.com.
Christopher A TanLabcorp Genetics Inc, 1400 16th Street, San Francisco, CA, 94103, USA.
Yuya KobayashiLabcorp Genetics Inc, 1400 16th Street, San Francisco, CA, 94103, USA.
Alexander WahlLabcorp Genetics Inc, 1400 16th Street, San Francisco, CA, 94103, USA.
Carlos ArayaInvitae Corporation, 1400 16th Street, San Francisco, CA, 94103, USA.
Alexandre ColavinInvitae Corporation, 1400 16th Street, San Francisco, CA, 94103, USA.
Flavia M FacioLabcorp Genetics Inc, 1400 16th Street, San Francisco, CA, 94103, USA.
Hillery MetzLabcorp Genetics Inc, 1400 16th Street, San Francisco, CA, 94103, USA.
Jason ReuterLabcorp Genetics Inc, 1400 16th Street, San Francisco, CA, 94103, USA.
Laure FrésardLabcorp Genetics Inc, 1400 16th Street, San Francisco, CA, 94103, USA.
Samskruthi R PadigepatiLabcorp Genetics Inc, 1400 16th Street, San Francisco, CA, 94103, USA.
David A StaffordLabcorp Genetics Inc, 1400 16th Street, San Francisco, CA, 94103, USA.
Robert L NussbaumInvitae Corporation, 1400 16th Street, San Francisco, CA, 94103, USA.
Keith NykampLabcorp Genetics Inc, 1400 16th Street, San Francisco, CA, 94103, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Variants of Uncertain Significance (VUS) in genetic testing for hereditary diseases burden patients and clinicians, yet clinical data that could reduce VUS are underutilized due to a lack of scalable strategies. We assessed whether a machine learning approach using genotype and phenotype data could improve variant classification and reduce VUS. In this cohort study of a multi-step machine learning approach, patient data from test requisition forms were used to distinguish patients with molecular diagnoses from controls ("patient score"). A generative Bayesian model then used patient scores and variant classifications to infer variant pathogenicity ("variant score"). The study included 3.5 million patients referred for clinical genetic testing across various conditions. Primary outcomes were model- and gene-level discrimination, classification performance, probabilistic calibration, and concordance with orthogonal pathogenicity measures. Integration into a semi-quantitative classification framework was based on posterior pathogenicity probabilities matching PPV ≥ 0.99/NPV ≥ 0.95 thresholds, followed by expert review. We generated 1,334 clinical variant models (CVMs); 595 showed high performance in both machine learning steps (AUROCpatient ≥ 0.8 and AUROCvariant ≥ 0.8) on held-out data. High-confidence predictions from these CVMs provided evidence for 5,362 VUS observed in 200,174 patients, representing 23.4% of all VUS observations in these genes. In 17 frequently tested genes, CVMs reclassified over 1,000 unique VUS, reducing VUS report rates by 9-49% per condition. In conclusion, a scalable machine learning approach using underutilized clinical data improved variant classification and reduced VUS.

Indexed as

Genetic TestingGenetic VariationBayes TheoremGenotypeHumansLanguageLarge Language ModelsMachine LearningPhenotype

Identifiers

PMID40266329
PMCPMC12170740

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.